Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter International and Takeda Pharmaceutical Company have completed a Development, License and Technology Transfer Agreement, under which the companies will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Subscribe to our email newsletter
As per the agreement, Baxter will exclusively license to Takeda its proprietary Vero cell-based influenza vaccine technology for the Japanese market.
The companies will jointly pursue development and licensure of an H5N1 influenza vaccine in Japan.
With assistance from Baxter, Takeda will pursue funding from the Japanese government for the construction of a Vero cell-based influenza manufacturing facility in Japan in order to fully implement the agreement.
Additionally, Baxter and Takeda will undertake a technology transfer to enable Takeda to manufacture the H5N1 influenza vaccine at full-scale by the end of Takeda’s 2013 fiscal year (ending 31 March 2014).
The agreement includes payments by Takeda to Baxter consisting of upfront cash payments, development cost reimbursements, payments upon the achievement of certain development, technology transfer, regulatory and commercial milestones, and royalties on the sale by Takeda of Vero cell-based influenza vaccines.
Baxter chairman and CEO said that the agreement with Takeda is an important milestone in extending the field of cell culture-based vaccine development and production.
Takeda president and CEO Yasuchika Hasegawa said that by collaborating with Baxter, they plan to establish an infrastructure for the production of pandemic vaccines in Japan.